Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 6/20 | 0.49 |
| ▸ | CASP1 | P29466 | 3/20 | 0.49 |
| ▸ | CASP8 | Q14790 | 3/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | ACACA | Q13085 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12529733 | 0.88 | CASP3 (0.52) | CASP3CASP1CASP8POLBALDH1A1 | |
| SCHEMBL12529736 | 0.86 | CASP1 (0.48) | CASP3CASP1CASP8SMN1; SMN2NPSR1 | |
| SCHEMBL7024933 | 0.86 | CASP1 (0.48) | CASP3CASP1CASP8SMN1; SMN2NPSR1 | |
| SCHEMBL8354504 | 0.83 | CASP3 (0.47) | CASP3CASP1CASP8ALDH1A1 | |
| SCHEMBL927372 | 0.78 | CASP1 (0.56) | CASP3CASP1CASP8SMN1; SMN2NPSR1 | |
| SCHEMBL12624138 | 0.75 | CASP1 (0.48) | CASP3CASP1CASP8SMN1; SMN2NPSR1 | |
| SCHEMBL12529803 | 0.74 | CASP1 (0.52) | CASP3CASP1CASP8NPSR1POLB | |
| SCHEMBL12529851 | 0.72 | CASP3 (0.41) | CASP3CASP1CASP8 | |
| SCHEMBL5497777 | 0.70 | HCRTR1 (0.42) | CASP1POLB | |
| SCHEMBL5497782 | 0.70 | HCRTR1 (0.42) | CASP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020045623-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2002-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045623-A1 | Caspase inhibitors and uses thereof | CASP3, CASP1, CASP2 | CASP3 1/4885CASP1 2/4885CASP8 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.